Entera Bio

Entera Bio Fixed Asset Turnover

The Fixed Asset Turnover of Entera Bio (ENTX) as of Nov 22, 2026 is 0.59. In the previous year, Fixed Asset Turnover was 1.45 — a change of -59.52% (lower).

Fixed Asset Turnover

0.59

YoY

-59.52%

Last updated:

Fixed Asset Turnover of Entera Bio is 2022 0.59 . Fixed Asset Turnover of Entera Bio was 2021 1.45 . It decreases by -59.52% lower compared to the previous year.

The Entera Bio Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
2.23 USD
Jan 1, 2019
0.51 USD
Jan 1, 2020
0.67 USD
Jan 1, 2021
1.45 USD
Jan 1, 2022
0.59 USD
The Entera Bio Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
0.59-59.52%
1.45+117.03%
0.67+30.39%
0.51-77.12%
2.23—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Fixed Asset Turnover of Entera Bio is 0.59 in 2022.

Fixed Asset Turnover of Entera Bio changed from 1.45 to 0.59, representing a -59.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Entera Bio

All Key Metrics — Entera Bio